Saturday 17 October 2026
Export SION’s income statement to Excel — free account
Sionna Therapeutics, Inc.
SION Healthcare Biotechnology
In the quarter to June 2026, EPS fell 61.0% and free cash flow fell 22.4%, each against the same quarter a year earlier.
3.89
0.19
−4.66%
Follow SION
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
20.05 | 22.60 | 20.61 | 25.61 |
+7 more quarters Free account |
Net Debt/EBITDA |
6.50 | 7.29 | 9.91 | 10.16 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.82 | 0.81 | 0.75 | |
Capex/Depreciation |
0.00 | 0.00 | 1.01 | 0.13 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.49) | (0.49) | (0.42) | (0.35) | |
Cash per Share |
4.67 | 4.81 | 5.90 | 5.61 | |
Shareholders Equity per Share |
5.89 | 6.42 | 7.68 | 7.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.89 | 6.42 | 7.68 | 7.27 | |
Free Cash Flow |
(22.22) | (21.84) | (16.83) | (15.32) | |
Working Capital |
205.35 | 211.18 | 229.71 | 242.48 | |
Capital Expenditures |
— | — | (0.20) | (0.09) | |
Net Current Asset Value |
198.66 | 204.13 | 222.30 | 234.73 | |
| Other line items | |||||
Quick Ratio |
19.57 | 22.11 | 20.14 | 25.21 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (0.49) | (0.42) | (0.34) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Average Payables |
0.72 | 3.56 | 0.98 | 1.10 | |
Average Assets |
317.65 | 337.36 | 255.85 | 195.61 | |
Average Common Equity |
301.10 | 319.99 | 71.56 | 103.39 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates